felin
infecti
periton
fip
sever
fatal
immuneaug
diseas
cat
popul
caus
fip
viru
fipv
virul
mutant
strain
felin
enter
coronaviru
fecv
current
treatment
prophylact
effect
vitro
antivir
properti
five
circular
triplehelix
form
oligonucleotid
tfo
rna
target
differ
region
virul
felin
coronaviru
fcov
strain
fipv
wsu
genom
test
fipvinfect
crandellre
felin
kidney
crfk
cell
rtqpcr
result
show
circular
tfo
rna
except
inhibit
fipv
replic
viral
genom
copi
number
decreas
significantli
log
virusinocul
cell
circular
tfo
rnastransfect
cell
furthermor
bind
circular
tfo
rna
target
viral
genom
segment
also
confirm
use
electrophoret
mobil
shift
assay
strength
bind
kinet
tfo
rna
target
region
demonstr
nanoitc
assay
conclus
circular
tfo
potenti
develop
antivir
agent
fipv
infect
felin
infecti
periton
viru
fipv
envelop
viru
nonseg
posit
sens
singlestrand
rna
genom
fipv
group
felin
coronaviru
fcov
famili
coronavirida
fcov
divid
two
biotyp
name
felin
enter
coronaviru
fecv
ubiquit
enter
biotyp
fcov
fipv
virul
biotyp
fcov
relationship
two
biotyp
still
remain
unclear
two
hypothes
propos
intern
mutat
theori
ii
circul
high
virulentlow
virul
theori
intern
mutat
theori
state
develop
fip
due
exposur
cat
variant
fcov
mutat
gain
abil
replic
within
macrophag
circul
high
virulentlow
virul
theori
explain
exist
distinct
pathogen
benign
lineag
virus
within
cat
popul
studi
shown
cat
detect
fecv
shed
faec
fecvposit
cat
develop
immunemedi
fatal
fip
diseas
preval
fip
among
felin
due
continu
cycl
infect
reinfect
fecv
indiscern
clinic
symptom
infect
cat
fecv
earli
stage
progress
develop
fipv
vaccin
fipv
attenu
temperaturesensit
strain
type
ii
fipv
induc
low
antibodi
titr
kitten
expos
fcov
howev
consider
controversi
safeti
efficaci
vaccin
sinc
vaccin
contain
type
strain
wherea
type
virus
preval
field
addit
antibodi
fipv
protect
infect
cat
enhanc
infect
monocyt
macrophag
via
mechan
known
antibodydepend
enhanc
besid
vaccin
sever
antivir
drug
ribavirin
biom
research
intern
interferon
immunosuppress
drug
use
treatment
fipvinfect
cat
mainli
suppress
inflammatori
detriment
immun
respons
howev
treatment
ineffect
henc
still
signific
unmet
medic
need
develop
effect
treatment
prophylact
fipv
infect
tripl
helix
form
oligonucleotid
tfo
defin
homopyrimidin
oligonucleotid
form
sequencespecif
tripl
helix
hoogsteen
bond
major
groov
complementari
homopyrimidinehomopurin
stretch
duplex
dna
furthermor
doubl
helic
rna
dnarna
hybrid
target
templat
tripl
helix
format
strand
composit
stabil
tripl
helic
complex
determin
henc
tfo
use
imped
gene
express
transcript
inhibit
viral
gene
oncogen
main
purpos
studi
develop
evalu
vitro
antivir
properti
circular
tfo
rna
fipv
replic
serotyp
ii
strain
wsu
atcc
grown
crfk
cell
serial
dilut
fipv
prepar
work
stock
confluent
plate
inocul
l
viru
dilutionwel
plate
incub
humidifi
incub
c
co
cytopath
effect
cpe
develop
observ
result
record
hour
viru
tissu
cultur
infect
dose
tcid
calcul
use
reed
muench
method
oligonucleotid
rna
tripl
helix
form
oligonucleotid
tfo
design
base
genom
sequenc
fipv
serotyp
ii
strain
wsu
access
tfo
specif
target
differ
region
fipv
genom
one
unrel
tfo
construct
tabl
specif
tfo
identifi
use
blast
search
ncbi
databas
design
linear
tfo
synthes
dharmacon
research
usa
wherebi
end
linear
tfo
modifi
phosphat
po
group
hydroxid
oh
group
respect
modif
necessari
circular
linear
tfo
process
circular
use
rna
ligas
ssrna
ligas
new
england
biolab
inc
england
carri
accord
manufactur
protocol
ligat
circular
tfo
rna
recov
ethanol
precipit
puriti
circular
tfo
rna
measur
use
spectrophotomet
denatur
urea
polyacrylamid
gel
electrophoresi
perform
describ
modif
briefli
denatur
urea
polyacrylamid
gel
prepar
polymer
minut
gel
prerun
v
minut
five
l
tfo
rna
mix
l
urea
load
buffer
heat
c
minut
immedi
chill
ice
run
gel
v
minut
final
gel
stain
ethidium
bromid
sigma
usa
view
biorad
gel
doc
xr
system
ca
usa
emsa
target
region
fipv
genom
synthes
dharmacon
research
usa
tabl
tfo
rna
mix
target
region
bind
buffer
contain
mm
trishcl
mm
mgcl
mmnacl
final
volum
l
subsequ
incub
c
hour
sampl
run
nativ
polyacrylamid
gel
v
cool
condit
stain
gel
view
biorad
gel
doc
xr
system
region
bind
strength
measur
use
nano
isotherm
titrat
calorimet
itc
ta
instrument
newcastl
uk
rna
sampl
mixtur
consist
circular
tfo
mm
incub
respect
synthet
target
region
mm
use
bind
buffer
diluent
experi
run
c
linject
total
inject
data
collect
everi
second
analyz
use
nanoanalyz
softwar
provid
manufactur
experi
conduct
crfk
cell
cellwel
seed
plate
reach
confluenc
hour
prior
transfect
one
hundr
nm
tfo
rna
separ
transfect
crfk
cell
use
hiperfect
transfect
reagent
qiagen
germani
per
manufactur
protocol
plate
incub
c
co
hour
cultur
infect
fipv
serotyp
ii
strain
wsu
hour
c
lwell
final
viral
inoculum
replac
fresh
mainten
media
mem
contain
fb
penstrep
virusinfect
uninfect
cell
maintain
posit
neg
control
respect
morpholog
cultur
record
hour
infect
sampl
harvest
time
point
store
c
prior
rna
extract
inhibit
differ
concentr
circular
rna
nm
nm
nm
nm
transfect
crfk
cell
plate
incub
hour
follow
viru
inocul
hour
c
cell
process
describ
madindarbi
canin
kidney
mdck
cell
atcc
concentr
cellwel
seed
plate
reach
confluenc
hour
prior
transfect
transfect
perform
one
hundr
nm
circular
tfo
rna
transfect
mdck
cell
follow
hour
highlight
bold
indic
bind
region
unrel
circular
tfo
respect
revers
transcriptas
quantit
realtim
pcr
rtqpcr
perform
use
biorad
realtim
system
biorad
usa
reaction
amplifi
final
volum
l
use
sensimix
sybr
norox
onestep
kit
biolin
uk
consist
l
sensimix
sybr
norox
one
step
reaction
buffer
forward
revers
primer
unit
ribosaf
rnase
inhibitor
l
templat
rna
absolut
quantif
approach
use
quantifi
qpcr
result
standard
curv
serial
dilut
viru
plot
quantif
amount
viru
sampl
quantifi
base
standard
curv
analysi
data
statist
analysi
perform
use
spss
data
repres
mean
se
three
independ
test
oneway
anova
tukey
post
hoc
test
use
analyz
signific
level
among
data
consid
signific
genom
play
import
role
viral
replic
select
target
bind
site
triplex
format
target
region
untransl
region
utr
open
read
frame
orf
untransl
region
utr
tabl
tfo
design
duplex
bind
singl
strand
target
region
reshap
triplex
end
duplex
tfo
ligat
linker
sequenc
clamp
cc
construct
circular
tfo
rna
denatur
page
assay
carri
ligat
process
determin
format
circular
tfo
shown
figur
circular
tfo
rna
migrat
faster
linear
tfo
rna
subject
denatur
page
target
region
bind
abil
determin
use
electrophoret
mobil
shift
assay
emsa
appear
slow
mobil
band
indic
success
hybrid
circular
tfo
rna
target
region
bind
abil
differ
tfo
rna
target
region
determin
emsa
figur
show
slow
mobil
band
show
lack
upward
shift
band
indic
possess
triplex
bind
abil
circular
tfo
rna
except
tfo
rna
studi
interact
hybrid
tfo
toward
target
region
crucial
sinc
stronger
bind
stabl
triplex
structur
form
shown
supplementari
figur
tabl
antivir
effect
circular
tfo
rna
investig
rtqpcr
assay
hour
transfect
result
show
viral
rna
genom
copi
number
cell
treat
respect
data
analyz
oneway
anova
tukey
post
hoc
test
show
signific
high
viral
rna
genom
copi
number
viru
inocul
cell
compar
circular
treatment
viral
rna
copi
circular
linear
unrel
circular
rna
transfect
cell
also
show
high
viral
rna
copi
number
show
signific
differ
infect
cell
figur
morpholog
chang
cell
also
captur
hour
transfect
cell
transfect
circular
appear
good
condit
follow
viru
inocul
cell
transfect
circular
linear
show
visibl
cytopath
effect
cpe
viru
inocul
cell
supplementari
figur
furthermor
cell
transfect
tfo
remain
viabl
indic
tfo
treatment
gener
toxic
cell
henc
result
illustr
capac
circular
tfo
rna
except
inhibit
fipv
replic
concentr
fipv
replic
circular
use
examin
doserespons
relationship
repres
tfo
experiment
condit
ident
previou
experi
except
concentr
nm
nm
nm
nm
signific
reduct
viral
rna
genom
copi
use
concentr
nm
concentr
caus
signific
reduct
copi
number
compar
virusinfect
cell
howev
signific
differ
detect
copi
number
concentr
figur
specif
tfo
toward
fipv
test
use
proper
repres
tfo
influenza
viru
new
jersey
analyz
data
use
oneway
anova
tukey
post
hoc
test
show
signific
reduct
copi
viral
rna
tfo
compar
influenza
viru
inocul
cell
supplementari
figur
complex
structur
figur
emsa
analysi
emsa
analysi
illustr
bind
circular
tfo
target
region
evidenc
upward
band
shift
bind
circular
tfo
except
circular
respect
target
form
complex
migrat
slower
unbound
tfo
repres
target
region
circular
repres
circular
respect
replic
process
meanwhil
fipv
translat
polyprotein
cleav
nonstructur
protein
assembl
replicationtranscript
complex
togeth
viral
protein
henc
develop
molecular
therapi
target
critic
region
may
provid
possibl
inhibit
fipv
replic
develop
antivir
therapi
fipv
use
sirna
viral
proteas
inhibitor
figur
doserespons
studi
inhibit
fipv
replic
concentr
nm
higher
show
signific
antivir
effect
nm
circular
rna
abl
reduc
viral
copi
number
log
nm
show
reduct
data
averag
independ
test
mean
se
significantli
differ
fipvinfect
group
potenti
new
treatment
fipv
infect
studi
circular
tripl
helix
form
oligonucleotid
tfo
rna
specif
target
short
region
viral
genom
triplex
format
design
evalu
target
utr
viral
genom
respect
target
differ
region
fipv
genom
prior
vitro
antivir
studi
ligat
circular
tfo
evalu
use
page
analysi
circularis
tfo
show
faster
migrat
pattern
compar
linear
tfo
howev
slight
variat
detect
tfo
figur
reason
clear
probabl
due
differ
length
tertiari
structur
tfo
lead
differ
migrat
rate
emsa
use
show
bind
capabl
circular
tfo
toward
target
region
fipv
genom
except
show
lack
format
complex
structur
upon
hybrid
figur
emsa
result
also
concur
antivir
studi
circular
tfo
except
abl
demonstr
signific
reduct
viral
rna
genom
copi
number
log
viru
inocul
cell
tfotransfect
cell
figur
howev
antivir
properti
detect
linear
tfo
unrel
circular
rna
confirm
antivir
activ
associ
specif
bind
circular
tfo
toward
target
region
furthermor
bind
circular
tfo
target
region
confirm
nanoitc
analysi
low
valu
high
stabil
allow
tfo
compet
effect
target
region
inhibit
transcript
cellfre
system
sinc
show
lowest
valu
tabl
antivir
properti
tfo
evalu
doserespons
studi
shown
figur
nm
show
similar
antivir
effect
indic
potenti
therapeut
applic
fipv
replic
howev
increas
concentr
nm
fail
reduc
viral
load
probabl
due
ineffici
transfect
reagent
transfect
tfo
cell
addit
viru
fast
replic
rate
upon
vitro
infect
previou
studi
growth
fipv
crfk
cell
show
hour
approxim
fipv
intern
crfk
cell
endocytosi
increas
hour
find
probabl
also
explain
reason
antivir
effect
detect
transfect
tfo
perform
virusinfect
cell
data
shown
antivir
properti
demonstr
circular
tfo
probabl
associ
bind
tfo
target
region
base
watsoncrick
hoogsteen
hydrogen
bond
enhanc
stabil
term
enthalpi
brought
join
togeth
two
three
strand
tripl
helix
proper
orient
therefor
triplex
format
tightli
bond
easi
detach
furthermor
circular
tfo
design
way
presenc
hydrogen
bond
donor
acceptor
purin
abl
form
two
hydrogen
bond
pyrimidin
base
form
one
addit
hydrogen
bond
incom
third
base
howev
variou
factor
may
limit
activ
tfo
cell
like
intracellular
degrad
tfo
limit
access
tfo
target
site
prevent
triplex
format
find
may
also
explain
inabl
design
inhibit
viru
replic
doserespons
studi
figur
variou
molecularbas
therapi
infecti
diseas
cancer
develop
test
howev
sirnabas
therapi
studi
extens
novel
antivir
anticanc
therapi
recent
mcdonagh
et
al
develop
sirna
antivir
activ
fipv
design
sirna
abl
reduc
copi
number
viral
genom
compar
virusinfect
cell
potenti
therapeut
applic
tfo
linear
tfo
conjug
psoralen
inhibit
transcript
human
immunodefici
proviru
tfo
inhibit
transcript
collagen
rat
fibroblast
also
report
addit
short
tfo
conjug
daunomycin
target
promot
region
oncogen
design
evalu
human
cancer
cell
studi
indic
flexibl
use
tfobas
oligonucleotid
potenti
molecularbas
therapi
studi
demonstr
short
circular
tfo
rna
mer
tabl
abl
inhibit
fipv
replic
bind
specif
target
region
fipv
genom
design
circular
tfo
except
show
signific
inhibitori
effect
fipv
replic
tfo
form
triplex
structur
show
antivir
effect
toward
fipv
replic
reason
fail
show
interact
target
region
antivir
activ
probabl
due
length
ie
mer
might
insuffici
triplex
format
upon
hybrid
figur
effect
enough
suppress
viral
rna
transcript
eventu
inhibit
viru
replic
nevertheless
inabl
show
antivir
effect
due
failur
format
function
tertiari
structur
triplex
format
rule
vitro
antivir
studi
show
antivir
properti
unrel
tfo
also
inabl
circular
inhibit
influenza
viru
infect
cell
confirm
specif
tfo
activ
conclus
circular
tfo
rna
potenti
develop
therapi
fipv
cat
howev
studi
tfo
specif
actual
mechan
circular
tfo
rna
transcript
alter
consequ
inhibit
viral
transcript
process
vivo
anim
studi
import
approach
work
therapi
futur
